Strategic Plan Question Detail
Interagency Autism Coordinating Committee (IACC) logo
Office of Autism Research Coordination (OARC) logo

Question 4: Which Treatments And Interventions Will Help? (Treatments)  

$68,123,890.33
Fiscal Year: 2010

Download 2010 Question 4 projects (EXCEL)
Note: Initial Sort is by Principal Investigator. Sorting by other columns is available by clicking on the desired column header.
Project Title Principal Investigator Strategic Plan Objective Institution
Treatment of sleep problems in children with autism spectrum disorder with melatonin: A double-blind, placebo-controlled study Hopkins, Bobbi Q4.S.A Baylor College of Medicine
Treatment of sleep problems in children with autism spectrum disorder with melatonin: A double-blind, placebo-controlled study Hopkins, Bobbi Q4.S.A Baylor College of Medicine
Autism Intervention Research Network on Physical Health (AIR-P network) Perrin, James Q4.S.A Massachusetts General Hospital
Cognitive-behavioral group treatment for anxiety symptoms in adolescents with high-functioning autism spectrum disorders Reaven, Judy Q4.S.A University of Colorado Denver
Preclinical testing of novel oxytocin receptor activators in models of autism phenotypes Jarstfer, Michael Q4.S.B University of North Carolina at Chapel Hill
Functional study of synaptic scaffold protein SHANK3 and autism mouse model Jiang, Yong-Hui Q4.S.B Duke University
Control of synaptic protein synthesis in the pathogenesis and therapy of autism Kelleher, Raymond Q4.S.B Massachusetts General Hospital
Behavioral and physiological consequences of disrupted Met signaling Levitt, Pat Q4.S.B University of Southern California
The genetics of restricted, repetitive behavior: An inbred mouse model Lewis, Mark Q4.S.B University of Florida
Serotonin, corpus callosum, and autism Lin, Rick Q4.S.B University of Mississippi Medical Center
Interaction between MEF2 and MECP2 in the pathogenesis of autism spectrum disorders - 1 Lipton, Stuart Q4.S.B Burnham Institute
Using Drosophila to model the synaptic function of the autism-linked NHE9 Littleton, J. Troy Q4.S.B Massachusetts Institute of Technology
Autism iPSCs for studying function and dysfunction in human neural development Loring, Jeanne Q4.S.B The Scripps Research Institute
Neuropharmacology of motivation and reinforcement in mouse models of autistic spectrum disorders Malanga, C.J. Q4.S.B University of North Carolina School of Medicine
NrCAM, a candidate susceptibility gene for visual processing deficits in autism Maness, Patricia Q4.S.B University of North Carolina at Chapel Hill
Modeling and pharmacologic treatment of autism spectrum disorders in Drosophila McDonald, Thomas Q4.S.B Albert Einstein College of Medicine of Yeshiva University
A mouse knock-in model for ENGRAILED 2 autism susceptibility Millonig, James Q4.S.B University of Medicine & Dentistry of New Jersey
16p11.2: defining the gene(s) responsible Mills, Alea Q4.S.B Cold Spring Harbor Laboratory
Novel models to define the genetic basis of autism Mills, Alea Q4.S.B Cold Spring Harbor Laboratory
Preclinical testing of novel oxytocin receptor activators in models of autism phenotypes Moy, Sheryl Q4.S.B University of North Carolina at Chapel Hill
Characterization of a novel mouse model of restricted repetitive behaviors Moy, Sheryl Q4.S.B University of North Carolina at Chapel Hill
Interaction between MEF2 and MECP2 in the pathogenesis of autism spectrum disorders -2 Nakanishi, Nobuki Q4.S.B Burnham Institute
Systematic analysis of neural circuitry in mouse models of autism Osten, Pavel Q4.S.B Cold Spring Harbor Laboratory
Role of L-type calcium channels in hippocampal neuronal network activity Owen, Scott Q4.S.B Stanford University
Novel probiotic therapies for autism Patterson, Paul Q4.S.B California Institute of Technology